The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than ...

Three out of four adults in the United States live with conditions that can increase the risk of severe illness. 9 Chronic ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Cambridge, USA-based mRNA vaccines company Moderna today announced the expansion of its US manufacturing capabilities with ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...